Celgene CEO Weighs In On Receptos Deal And Its Timing

Loading...
Loading...

Celgene Corporation CELG announced on Tuesday that it will be acquiring Receptos Inc RCPT in a $7.3 billion deal.

Robert Hugin, Celgene chairman and CEO, was on CNBC Wednesday to weigh in on the deal and its timing.

Ozanimod: Key Driver

"Exciting time for us and, I think, there are a couple of drugs in the pipeline, but clearly the Ozanimod is the key driver here," Hugin said. "And it has been sort of through a lot of risks and trials already, and the mechanism is been proven [sic.] by other compounds. So, it's very exciting for us."

'Now Is The Time To Strike'

On the timing of the deal, Hugin said, "We really think the operating momentum of the company is so strong, and that's one of the reasons why the timing works on this deal and [...]we preannounced our second-quarter results. Twenty-two (22) percent year-over-year revenue growth, 37 percent year-over-year earnings growth. So, very strong operating performance. Now is the time to strike, build for the future."

Excited About Promise Of The Future

"Over this past couple of months, we have been able to identify and execute three significant deals that really enhance our long-term growth prospects. And not just for the next five or six years, but the next 10 or 15 years.

"We are building our franchises and really focused about doing that and we are just so excited about the promise of the future," Hugin concluded.

Image Credit: Public Domain
Loading...
Loading...
Posted In: BiotechCNBCHealth CareTop StoriesMediaOzanimodRobert Hugin
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...